Sympathetic nervous system in heart failure.
Cohn
Jay N
JN
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D002395:Catecholamines / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D006325:Heart Atria / Q000294:innervation; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D051379:Mice; D009638:Norepinephrine / Q000097:blood; D011110:Polymorphism, Genetic; D017729:Presynaptic Terminals / Q000187:drug effects; D018341:Receptors, Adrenergic, alpha-2 / Q000172:deficiency / Q000235:genetics; D012084:Renin-Angiotensin System / Q000187:drug effects; D012107:Research Design; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D014661:Vasoconstriction; D020257:Ventricular Remodeling / Q000187:drug effects
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D018341:Receptors, Adrenergic, alpha-2; D009638:Norepinephrine